Eli Lilly's logo is shown in one of the company's offices in San Diego, California, on September 17, 2020.
Mike Blake | Reuters
Eli Lilly On Thursday he walked his 2025 guide and recorded profits from the second quarter that exceeded estimates on the strong demand for their great weight loss and diabetes medications.
The company raised its tax sales guide from 2025 to $ 60 billion to $ 62 billion, from an earlier perspective from $ 58 billion to $ 61 billion in underlying strength throughout its business. The pharmaceutical giant also hopes that its adjusted fiscal profits 2025 will be between $ 21.75 to $ 23, above an earlier guide of $ 20.78 and $ 22.28 per share.
Eli Lilly said the guide reflects the existing tariffs of President Donald Trump as of August 7, but does not include its planned levies on imported pharmaceutical products to the United States.
Also on Thursday, Eli Lilly published tests of trial in the long -awaited stage about its experimental obesity pill, orforglipron, whose highest dose helped patients lose more than 12% of their body weight. That was under the expectations of Wall Street, sending shares to more than 11% in the negotiation prior to the market on Thursday.
“I feel good with the company's value. Investors have to decide what they think,” said Eli Lilly CEO, David Ricks, “Squawk Box” of CNBC. “But Lilly is rolling, and you look at the rhythm and increase, strong growth in the posterior half, we are excited about the future for our company and for patients who need our products.”
The company's diabetes treatment, Mounjaro exceeded expectations for the first quarter, raising almost $ 5.2 billion in income. That increased 68% since the same period a year ago.
The weight loss drug of Eli Lilly Zepbound also exceeded estimates, reserving $ 3.38 billion in sales for the quarter, a huge 172% since the period of year more than the year.
Analysts expected Mounjaro and Zepbound to generate $ 4.49 billion and $ 3.06 billion in sales, respectively, according to Streetacount estimates.
“The Tirzepatide, which is Mounjaro and Zepbound, will probably become the best selling drug in the industry in its third year in the market,” Ricks told CNBC. “And we have much more in the pipe.”
This is what Eli Lilly reported for the second quarter compared to what Wall Street expected, based on a LSEG analysts survey:
- Profit per action: $ 6.31 adjusted compared to $ 5.57 expected
- Revenue: $ 15.56 billion compared to $ 14.71 billion expected
The company registered income of the second quarter of $ 15.56 billion, 38% more than the same period of the previous year.
Sales in the United States increased 38% to $ 10.81 billion. Eli Lilly said it was driven by a 46% increase in volume, or the number of recipes or units sold, for their products, mainly for Mounjaro and Zepbound. That was partially compensated by the lowest prices of medicines, the company said.
The pharmaceutical giant reserved a net income of $ 5.66 billion, or $ 6.29 per share, for the second quarter. That is compared to the net income of $ 2.97 billion, or $ 3.28 per share, a year earlier.
Excluding unique articles associated with the value of intangible assets and other adjustments, Eli Lilly registered profits of $ 6.31 per share for the second quarter.
The results also occur when Eli Lilly and other medications are preparing for levies on pharmaceutical products imported to the United States and face their calls at the lowest prices of medicines in the country.
The president sent letters to Eli Lilly and other companies last week that asked them to take measures to reduce medicines prices before September 29. The measure occurred after Trump in May signed an executive order that revived a controversial plan, the most favored “nation policy”, which aims to reduce drug costs by linking the prices of some medications in the US. UU. To the United States to which it significantly lower abroad.
